NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MRSN Stock Alerts $2.71 +0.25 (+10.16%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.47▼$2.7350-Day Range$2.47▼$5.8552-Week Range$0.80▼$9.62Volume2.81 million shsAverage Volume1.66 million shsMarket Capitalization$328.72 millionP/E RatioN/ADividend YieldN/APrice Target$6.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mersana Therapeutics alerts: Email Address Mersana Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside131.9% Upside$6.29 Price TargetShort InterestBearish9.00% of Shares Sold ShortDividend StrengthN/ASustainability-0.69Upright™ Environmental ScoreNews Sentiment0.54Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.10 out of 5 starsMedical Sector173rd out of 921 stocksPharmaceutical Preparations Industry65th out of 428 stocks 4.4 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mersana Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.00% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Mersana Therapeutics has recently increased by 3.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMersana Therapeutics has received a 58.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mersana Therapeutics is -0.69. Previous Next 2.0 News and Social Media Coverage News SentimentMersana Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 8.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mersana Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Mersana Therapeutics Stock (NASDAQ:MRSN)Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More MRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRSN Stock News HeadlinesMay 10, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comMersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 10, 2024 | americanbankingnews.comStock Traders Buy High Volume of Call Options on Mersana Therapeutics (NASDAQ:MRSN)May 9, 2024 | investorplace.comMRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | americanbankingnews.comMersana Therapeutics (MRSN) Scheduled to Post Earnings on ThursdayMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.May 3, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comMersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024April 20, 2024 | seekingalpha.comMRSN Mersana Therapeutics, Inc.April 5, 2024 | morningstar.comMersana Therapeutics Inc MRSNApril 4, 2024 | globenewswire.comMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 ExpertsMarch 1, 2024 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | nasdaq.comGuggenheim Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming MilestonesMarch 1, 2024 | msn.comTruist Securities Upgrades Mersana Therapeutics (MRSN)March 1, 2024 | msn.comWedbush Upgrades Mersana Therapeutics (MRSN)February 29, 2024 | markets.businessinsider.comExpert Outlook: Mersana Therapeutics Through The Eyes Of 5 AnalystsFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | realmoney.thestreet.comGuggenheim gets more bullish on Mersana Therapeutics, upgrades sharesFebruary 29, 2024 | finance.yahoo.comAn Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% UndervaluedFebruary 29, 2024 | finance.yahoo.comMersana Therapeutics Full Year 2023 Earnings: Revenues DisappointFebruary 29, 2024 | finance.yahoo.comQ4 2023 Mersana Therapeutics Inc Earnings CallFebruary 28, 2024 | finanznachrichten.deMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees123Year FoundedN/APrice Target and Rating Average Stock Price Target$6.29 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+131.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-465.80% Pretax Margin-465.80% Return on Equity-282.36% Return on Assets-62.64% Debt Debt-to-Equity Ratio0.63 Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$36.85 million Price / Sales8.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book8.74Miscellaneous Outstanding Shares121,300,000Free Float106,140,000Market Cap$328.72 million OptionableOptionable Beta1.61 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Martin H. Huber M.D. (Age 63)President, CEO & Director Comp: $44kMr. Brian C. DeSchuytner (Age 45)Senior VP, CFO & COO Comp: $626.32kDr. Timothy B. Lowinger Ph.D. (Age 60)Senior VP and Chief Science & Technology Officer Comp: $666.3kMs. Alejandra Veronica Carvajal J.D. (Age 50)Senior VP, Secretary & Chief Legal Officer Comp: $606.51kMr. Mikhail Papisov Ph.D.Co-FounderMr. Ashish Mandelia (Age 49)VP, Controller & Chief Accounting Officer Mr. Jason FredetteSenior Vice President of Investor Relations & Corporate CommunicationsMr. Chuck MillerSenior Vice President of Regulatory AffairsMr. Marc DamelinExe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.Dr. Tushar Misra Ph.D. (Age 63)Senior VP & Chief Manufacturing Officer Comp: $485.89kMore ExecutivesKey CompetitorsAnnexonNASDAQ:ANNXBiomea FusionNASDAQ:BMEAHeron TherapeuticsNASDAQ:HRTXKorro BioNASDAQ:KRROLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 36,782 shares on 5/10/2024Ownership: 5.172%Acadian Asset Management LLCBought 293,115 shares on 5/10/2024Ownership: 0.387%Russell Investments Group Ltd.Bought 8,575 shares on 5/8/2024Ownership: 0.008%Susquehanna Fundamental Investments LLCBought 234,116 shares on 5/7/2024Ownership: 0.193%SG Americas Securities LLCSold 5,713 shares on 5/7/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions MRSN Stock Analysis - Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRSN shares. View MRSN analyst ratings or view top-rated stocks. What is Mersana Therapeutics' stock price target for 2024? 7 brokerages have issued 1 year price targets for Mersana Therapeutics' stock. Their MRSN share price targets range from $5.00 to $9.00. On average, they anticipate the company's stock price to reach $6.29 in the next twelve months. This suggests a possible upside of 131.9% from the stock's current price. View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts. How have MRSN shares performed in 2024? Mersana Therapeutics' stock was trading at $2.32 at the beginning of 2024. Since then, MRSN stock has increased by 16.8% and is now trading at $2.71. View the best growth stocks for 2024 here. When is Mersana Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our MRSN earnings forecast. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business earned $9.25 million during the quarter, compared to analysts' expectations of $8.50 million. Mersana Therapeutics had a negative net margin of 352.01% and a negative trailing twelve-month return on equity of 226.07%. The company's revenue was up 18.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.52) earnings per share. What ETF holds Mersana Therapeutics' stock? Tema Oncology ETF holds 19,465 shares of MRSN stock, representing 0.37% of its portfolio. What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.17%), ClariVest Asset Management LLC (0.39%), Acadian Asset Management LLC (0.39%), Susquehanna Fundamental Investments LLC (0.19%), BNP Paribas Financial Markets (0.07%) and Mirae Asset Global Investments Co. Ltd. (0.04%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Lawrence M Alleva, Mohan Bala, Timothy B Lowinger and Tushar Misra. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRSN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
